psychemedics corp (PMD:NASDAQ CM)
psychemedics corp (PMD) Snapshot
|
Open
$11.33
|
Previous Close
$11.47
|
|
|
Day High
$11.57
|
Day Low
$11.33
|
|
|
52 Week High
10/8/12 - $12.49
|
52 Week Low
06/6/12 - $9.46
|
|
|
Market Cap
60.7M
|
Average Volume 10 Days
7.9K
|
|
|
EPS TTM
$0.57
|
Shares Outstanding
5.3M
|
|
|
EX-Date
05/15/13
|
P/E TM
20.1x
|
|
|
Dividend
$0.60
|
Dividend Yield
5.23%
|
Related News
psychemedics corp (PMD) Related Businessweek News
No Related Businessweek News Foundpsychemedics corp (PMD) Details
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company’s testing methods utilize a patented technology that focuses on liquefying hair and releasing drugs trapped in the hair without destroying the drugs. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, and amphetamines; and opiates, including heroin, hydrocodone, hydromorphone, oxycodone, and codeine. The Company’s tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which shows a pattern of individual drug use over a longer period of time. Psychemedics Corporation offers its services to employers for applicant and employee testing; physicians, treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children’s drug use; and Fortune 500 companies and small to mid-size corporations. The company was founded in 1985 and is headquartered in Acton, Massachusetts.
psychemedics corp (PMD) Top Compensated Officers
psychemedics corp (PMD) Key Developments
Psychemedics Corp. announced that Sarah Ashby has been promoted to the position of Vice President and General Counsel. In this role, Sarah is responsible for directing and managing all of the company's legal activities and reports to the company's CEO. Sarah joined Psychemedics in April 2012 as Associate General Counsel after 10 years in private practice focusing on civil litigation, FDA regulation and government investigations.
Psychemedics Corp. reported unaudited earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported revenues of $6,432,442 compared to $6,243,855 a year ago. Operating income was $1,202,192 compared to $1,376,806 a year ago. Net income before provision for income taxes was $1,293,605 compared to $1,377,316 a year ago. Net income and comprehensive income was $822,345 or $0.16 basic and diluted per share compared to $827,491 or $0.16 basic and diluted per share a year ago.
Psychemedics Corporation announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 17, 2013 to be paid on May 30, 2013.
| Recently Viewed | |||
| PMD:US | $11.47 USD | 0.00 |  |
| Company | Last | Change |
| Enzo Biochem Inc | $2.25 USD | 0.00 |
| Genomic Health Inc | $36.85 USD | -0.53 |
| NeoGenomics Inc | $3.73 USD | +0.03 |
| OraSure Technologies Inc | $4.31 USD | -0.04 |
| Response Genetics Inc | $1.40 USD | -0.01 |
| View Industry Companies | ||
Industry Analysis
PMD
Industry Average
| Valuation | PMD | Industry Range |
| Price/Earnings | 20.1x |
|
| Price/Sales | 2.4x |
|
| Price/Book | 5.3x |
|
| Price/Cash Flow | 20.2x |
|
| TEV/Sales | 2.3x |
|
Post a JobJobs
Sponsored Financial Commentaries
Sponsored Links
To contact PSYCHEMEDICS CORP, please visit www.psychemedics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
